Evaluating Drug Safety from Real-World Evidence: Congratulating Vizuro Team’s Contribution to Hematology Research
- Vizuro team
- Jul 8
- 1 min read
Updated: Sep 8
We're excited to share that a recent academic paper co-authored by our Data Scientist. Ling-Yu Cai, along with a team of MD/PhD collaborators, has been accepted for publication in the Annals of Hematology. The study, titled “A Pharmacovigilance Study of Adverse Events Associated with Polycythemia Vera Treatments Using the FDA Adverse Event Reporting System (FAERS) Database”, reflects a strong commitment to using data-driven approaches in clinical research.
This publication not only marks a personal milestone for Ling-Yu Cai but also echoes our belief at Vizuro in the transformative potential of AI and structured data analysis across medical domains.
As we continue to develop domain-specific solutions, we’re inspired by how large-scale real-world datasets — such as FAERS — can uncover insights that improve patient safety, drug evaluation, and clinical decision-making.
We congratulate our team for this academic recognition and look forward to deepening the intersection between AI and pharmacovigilance in future projects.
📌 Stay tuned as we explore how AI can accelerate evidence-based research and amplify the impact of real-world medical data.
Ling-Yu Cai is a data scientist at Vizuro with a background in biostatistics. She has authored several publications in pediatric anesthesiology, critical care research, and hematology pharmacovigilance. She is actively exploring ways to contribute to the application of AI in the medical field.
